Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MGMT promoter methylation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2
MGMT promoter methylation	Anaplastic Astrocytoma	MGMT promoter methylation	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT promoter methylation	Ewing Sarcoma	MGMT promoter methylation	Ewing Sarcoma	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	cilengitide Sensitive: C3 – Early Trials cilengitide Sensitive : C3	cilengitide Sensitive: C3 – Early Trials cilengitide Sensitive : C3
MGMT promoter methylation	Glioma	MGMT promoter methylation	Glioma	temozolomide + carmustine Sensitive: C3 – Early Trials temozolomide + carmustine Sensitive : C3	temozolomide + carmustine Sensitive: C3 – Early Trials temozolomide + carmustine Sensitive : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
MGMT promoter methylation	Glioma	MGMT promoter methylation	Glioma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	AV-GBM-1 Sensitive: C3 – Early Trials AV-GBM-1 Sensitive : C3	AV-GBM-1 Sensitive: C3 – Early Trials AV-GBM-1 Sensitive : C3
MGMT promoter methylation	Neuroendocrine Tumor	MGMT promoter methylation	Neuroendocrine Tumor	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MGMT promoter methylation	Glioma	MGMT promoter methylation	Glioma	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3
MGMT promoter methylation	Colorectal Cancer	MGMT promoter methylation	Colorectal Cancer	FOLFOX Resistant: C3 – Early Trials FOLFOX Resistant : C3	FOLFOX Resistant: C3 – Early Trials FOLFOX Resistant : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide + PAC-1 Sensitive: C3 – Early Trials temozolomide + PAC-1 Sensitive : C3	temozolomide + PAC-1 Sensitive: C3 – Early Trials temozolomide + PAC-1 Sensitive : C3